Return to Home

DexCom, Inc.

DXCM

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
October 21, 2024

Days Left:
-114

calendar

DexCom, Inc. Form












Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Allegations

According to the complaint, on July 25, 2024, Dexcom announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on their execution of “several key strategic initiatives” which “did not meet [their] high standards.” Investors and analysts reacted immediately to DexCom’s revelation. The price of DexCom’s common stock declined dramatically. From a closing market price of $107.85 per share on July 25, 2024, DexCom’s stock price fell to $64.00 per share on July 26, 2024, a decline of about 40.66% in the span of just a single day.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of DexCom purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in DexCom during the relevant time frame, you have until October 21, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Find More Cases

Ticker Symbol Company Name Join Deadline
APLT Applied Therapeutics, Inc. February 18, 2025 Join
BIOA BioAge Labs, Inc. March 10, 2025 Join
PCRX Pacira BioSciences, Inc. March 14, 2025 Join
NVO Novo Nordisk A/S March 25, 2025 Join
GO Grocery Outlet Holding Corp. March 31, 2025 Join
NEM Newmont Corporation April 01, 2025 Join
GSK GSK plc April 07, 2025 Join
NTLA Intellia Therapeutics, Inc. April 14, 2025 Join